J. Goldman & Co’s MacroGenics MGNX Stock Holding History

J. Goldman & Co’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-46,417	Closed	-$1.48M	–	467
2021 Q1	$1.48M	Buy	+46,417	New	+$1.13M	0.05%	266

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

J. Goldman & Co's MGNX Position: Q2 2021 in Review

J. Goldman & Co sold out of MacroGenics (MGNX) in Q2 2021, closing a stake of 46,417 shares — an estimated $1.48M sold.

J. Goldman & Co first reported a position in MGNX in Q1 2021 and held it in 1 quarter. The position peaked at $1.48M in Q1 2021. 149 funds tracked by Wall St. Rank hold MGNX as of Q2 2021.

J. Goldman & Co reported no remaining MacroGenics position as of Q2 2021 after selling out during the quarter.
J. Goldman & Co sold 46,417 MacroGenics shares in Q2 2021, an estimated $1.48M.
J. Goldman & Co first reported a position in MacroGenics in Q1 2021 and held it in 1 quarter.
J. Goldman & Co's MacroGenics position peaked at $1.48M in Q1 2021.
149 funds tracked by Wall St. Rank held MacroGenics as of Q2 2021.

Based on J. Goldman & Co's 13F filing for Q2 2021, filed 16 Aug 2021.